welcome
CNBC

CNBC

Health

Health

Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat

CNBC
Summary
Nutrition label

75% Informative

Danish pharmaceutical giant Novo Nordisk reports better-than-expected rise in net profit.

Sales of popular Wegovy obesity drug hit 17.36 billion Danish kroner over the period.

For 2025 , company now sees sales growth of 13% to 21% at constant exchange rates.

CEO Lars Fruergaard Jørgensen attributed reduced forecast to rising competition from compounded weight loss drugs in the U.S ..

VR Score

83

Informative language

91

Neutral language

13

Article tone

formal

Language

English

Language complexity

65

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links